Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study
International Journal of Radiation Oncology*Biology*Physics · 2024
DOI: 10.1016/j.ijrobp.2023.07.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Katharina Brück und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Amsterdam University Medical Centers, Amsterdam, The Netherlands; Netherlands Comprehensive Cancer Organization, Nijmegen…. Hauptthemen laut MEDLINE: Urinary Bladder, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: ZonMw, KWF Kankerbestrijding.
Abstract (Originalsprache)
PURPOSE: Although level I evidence is lacking that radical cystectomy (RC) is superior to bladder-preserving therapy (BPT), RC is still advocated as the recommended treatment in patients with nonmetastatic muscle-invasive bladder cancer (MIBC). This study sought to compare the survival of patients with MIBC treated with BPT versus those treated with RC. METHODS AND MATERIALS: All patients with nonmetastatic MIBC diagnoses were identified via the population-based Netherlands Cancer Registry. Only patients treated with BPT or RC were included. The primary endpoint was 2-year disease-free survival (DFS), defined as time from start of treatment until locoregional recurrence, distant metastasis, or death. The secondary endpoint was overall survival (OS). Inverse propensity treatment weighting (IPTW) was used based on propensity scores to adjust for baseline differences between treatment groups. Survival was analyzed with Kaplan-Meier and Cox proportional hazards models. RESULTS: A total of 1432 patients were included, of whom 1101 underwent RC and 331, BPT. Median follow-up was 39 months (range, 27-51 months). The IPTW-adjusted 2-year DFS was 61.5% (95% CI, 53.5%-69.6%) with BPT and 55.3% (95% CI, 51.6%-59.1%) with RC, with an adjusted hazard ratio of 0.84 (95% CI, 0.69-1.05). The adjusted 2-year OS for patients treated with BPT versus RC was 74.0% (95% CI, 67.0%-80.9%) versus 66.0% (95% CI, 62.7%-68.8%), respectively, with an adjusted hazard ratio of 0.80 (95% CI, 0.64-0.98). CONCLUSIONS: There was no statistically significant difference between the 2-year DFS of patients treated with BPT and RC. We propose that both RC and BPT should be offered as a curative treatment option to eligible patients with nonmetastatic MIBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiotherapy, Amsterdam University Medical Centers, Amsterdam, The Netherlands; Netherlands Comprehensive Cancer Organization, Nijmegen, The Netherlands. Electronic address: k.brueck@amsterdamumc.nl.
- Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands; Netherlands Comprehensive Cancer Organization, Nijmegen, The Netherlands.
Förderung
- ZonMw
- KWF Kankerbestrijding
Zitieren
APA
Brück, K., Meijer, R. P., Boormans, J. L., Kiemeney, L. A., Witjes, J. A., van Hoogstraten, L. M. C., van der Heijden, M. S., Donders, A. R., Franckena, M., Uyl de Groot, C. A., Leliveld, A. M., Aben, K. K. H., & Hulshof, M. C. C. M. (2024). Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.07.027
Vancouver
Brück K, Meijer RP, Boormans JL, Kiemeney LA, Witjes JA, van Hoogstraten LMC, et al. Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2023.07.027
BibTeX
@article{Brck2024,
author = {Brück, Katharina and Meijer, Richard P and Boormans, Joost L and Kiemeney, Lambertus A and Witjes, J Alfred and van Hoogstraten, Lisa M C and van der Heijden, Michiel S and Donders, A Rogier and Franckena, Martine and Uyl de Groot, Carin A and Leliveld, Annemarie M and Aben, Katja K H and Hulshof, Maarten C C M},
title = {Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
doi = {10.1016/j.ijrobp.2023.07.027}
}
EUVIMED